Published in Oncogene on February 24, 2005
Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A (2006) 4.08
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell (2007) 1.47
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol (2005) 1.22
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell (2013) 1.15
Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol (2007) 0.90
Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective. J Interferon Cytokine Res (2013) 0.89
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. Anticancer Res (2009) 0.87
The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Mol Cell Biol (2013) 0.87
Meta-analysis identifies NF-κB as a therapeutic target in renal cancer. PLoS One (2013) 0.83
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
USP9X destabilizes pVHL and promotes cell proliferation. Oncotarget (2016) 0.75
VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1. J Cell Biol (2017) 0.75
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem (2003) 2.88
Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene (2003) 1.31
Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell (2008) 1.27
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol (2005) 1.22
Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. Blood (2002) 1.20
Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res (2006) 1.14
Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol (2008) 1.09
Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene (2002) 1.07
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther (2004) 1.06
Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood (2003) 1.06
NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res (2010) 1.03
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther (2007) 1.02
Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology (2004) 0.88
Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. Cancer Res (2013) 0.85
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res (2003) 0.85
High efficiency vortex trapping of circulating tumor cells. Biomicrofluidics (2015) 0.77